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Pre-Clinical background
Natriuretic peptides were identified as regulatory diuretic-
natriuretic substances responsible for salt and water
homeostasis and as hormones lowering blood pressure.
Urodilatin is a natriuretic peptide type A which is synthe-
sized in the kidney and generated from the prohormone
ANP-1-126. While the circulating ANP-99-126 is synthe-
sized in the heart atrium and processed during exocytosis
Urodilatin (ANP-95-126) is differentially processed in the
kidney and detected only in urine.
Physiologically, Urodilatin acts in a paracrine fashion.
After release from distal tubular kidney cells into the tubu-
lar lumen, Urodilatin binds to luminal NPR-A-receptors
in the collecting duct resulting in a cGMP-dependent sig-
nal transduction. cGMP generation is followed by an
interaction with the amiloride-sensitive sodium channel
which induces diuresis and natriuresis. In this way,
Urodilatin regulates fluid balance and sodium homeosta-
sis. Moreover, Urodilatin excretion and natriuresis are in
turn dependent on different physiological states, such as
directly on sodium homeostasis.
Animal models were used to further investigate Urodila-
tin's clinical potential. Urodilatin given intravenously in
acute renal failure-models induced strong diuretic and
natriuretic effects while in congestive heart failure benefi-
cial hemodynamic effects were demonstrated. Urodilatin
was also shown to relax bronchi in animal models with
drug-induced bronchoconstriction. These renal, pulmo-
nary, and cardiovascular effects indicated that Urodilatin
is a putative drug for several related diseases.
Clinical background
Urodilatin was then used in the treatment and prophy-
laxis of acute renal failure following major surgery and
heart transplantation. A first pilot study in patients with
acutely decompensated heart failure demonstrated bene-
ficial hemodynamic effects of Urodilatin and treatment of
asthmatic patients showed beneficial effects of Urodilatin
on pulmonary function such as an increase in forced
expiratory volume.
Conclusion
Urodilatin is a natriuretic peptide synthesized in the kid-
ney. Based on its pharmacological profile Urodilatin is a
promising drug-candidate for different clinical indica-
tions.
from 2nd International Conference of cGMP Generators, Effectors and Therapeutic Implications
Potsdam, Germany, 10–12 June, 2005
Published: 16 June 2005
BMC Pharmacology 2005, 5(Suppl 1):S35 doi:10.1186/1471-2210-5-S1-S35
<supplement> <title> <p>2nd International Conference of cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts</note> </supplement>
